The cytokine microenvironment modulates CD4 T cell differentiation causing the shift of naïve CD4 T cells into different cell subsets. This process is also regulated by modulators such as vasoactive intestinal peptide (VIP), a neuropeptide with known immunomodulatory properties on CD4 T cells that exert this action through specific receptors, vasoactive intestinal peptide receptor (VPAC) 1 and VPAC 2 . Our results show that the pattern of VIP receptors expression ratio is modified during Th17 differentiation. In this report, we evaluate the capacity of VIP to modulate naïve human cells into Th17 cells in vitro by analyzing their functional phenotype. The presence of VIP maintains the nonpathogenic profile of Th17-polarized cells, increases the proliferation rate, and decreases their Th1 potential. VIP induces the upregulation of the STAT3 gene interaction with the VPAC 1 receptor during the onset of Th17 differentiation. Moreover, RARrelated orphan receptor C (RORC), RAR-related orphan receptor A (RORA), and interleukin (IL)-17A genes are upregulated in the presence of VIP through interaction with VPAC 1 and VPAC 2 receptors. Interestingly, VIP induces the expression of the IL-23R gene through interaction with the VPAC 2 receptor during the expansion phase. This is the first report that describes the differentiation of naïve human T cells to Th17-polarized cells in the presence of VIP and demonstrates how this differentiation regulates the expression of the VIP receptors.
Introduction
The cytokine microenvironment and antigen-presenting cells drive in vivo differentiation and clonal expansion of naïve helper T cells, converting them to different effector cells with specific roles. Naïve human CD4 T cells can be committed to four major cells lineages, namely Th1, Th2, Th17, and induced regulatory T cells, on the basis of their cytokine and transcription factor (master regulator) signature (Zhu and Paul 2010) . The cytokine signature profile of Th17 cells is formed by several cytokines such as interleukin (IL)-17A, IL-17F, IL-21, and IL-22. Th17 cells are also characterized by the expression of chemokine receptors such as CCR6 and cytokine receptors such as IL-23R and IL-21R. Moreover, Th17 cells can secrete to a lesser extent interferon gamma (IFN-γ), IL-10, IL-9, IL-2, and other cytokines. The final effector functions of Th17 cells depend on the specific combination of the cytokines produced (Zhu and Paul 2008; Korn et al. 2009; Zhu and Paul 2010; Ghoreschi et al. 2011; Hirota et al. 2012) . Increasing evidence points to a heterogeneous and inherent phenotypic instability in this subset (Ghoreschi et al. 2011; Hirota et al. 2012; Sundrud and Trivigno 2013) . Th17 cells are susceptible to changing to Th1, most likely due to epigenetic regulation (Murphy and Stockinger 2010; O'Shea and Paul 2010; Zhu and Paul 2010; Hirota et al. 2012) .
The inflammatory microenvironment causes Th17 cells a separate Th subset with a homeostatic role, able to clear pathogens that are less efficiently resolved by Th1 or Th2 (Chen and O'Shea 2008; Acosta-Rodriguez et al. 2007; Cua and Tato 2010) . By contrast, Th17 cells have also been related to organ-specific autoimmune diseases (Korn et al. 2009; Hirota et al. 2012; Marwaha et al. 2012) . In order to understand the potential role of Th17 cells in the development of massive inflammation and autoimmune diseases, it is important to know the regulatory mechanisms involved in their differentiation, proliferation, and function. Inhibitory cytokines, nuclear receptors, metabolic sensors, inhibitors of STATs, microRNAs (Hirahara et al. 2010; Bi and Yang 2012; Hirota et al. 2012 ) and probably immunomodulatory neuropeptides, are able to modulate Th17 cells.
Vasoactive intestinal peptide (VIP) is a ubiquitous neuropeptide that plays important regulatory roles in many physiological processes through binding to its specific receptors, vasoactive intestinal peptide receptor (VPAC) 1 and VPAC 2 (Couvineau and Laburthe 2012; Harmar et al. 2012 ). In the immune system, VIP can modulate both innate and adaptive immunity, showing predominantly anti-inflammatory and immunomodulatory actions. In vivo mouse data indicate that VIP treatment may have a promising role in the treatment of inflammatory and autoimmune diseases (Delgado et al. 2001; Gomariz et al. 2006; Lodde et al. 2006; Arranz et al. 2008; Calafat et al. 2009; Smalley et al. 2009; Gomariz et al. 2010) .
In several animal models of inflammation and autoimmune diseases, it has been described that VIP decreases cytokine expressions related to Th17 cells (Abad et al. 2005; Leceta et al. 2007; Jimeno et al. 2010 ). However, in vitro studies using mouse CD4 + T cells have reported that VIP plus transforming growth factor beta (TGF-β) promote their differentiation to a Th17 subset in a VPAC 1 -dependent manner (Yadav et al. 2008) . Thus far, the role of VIP in human Th17 cells remains unclear.
Th17 cells are considered a major link between innate and adaptive immune responses, having a critical role in normal host defense (Graeber and Olsen 2012) . This important scenery demands a better understanding of how these cells work and how they may be modulated by the microenvironment in a normal host and within the framework of autoimmune disease. Given the multiple effects of VIP on immune microenvironments and its immunomodulatory role in human autoimmune diseases, it is important to better understand the influence of VIP during human Th17 cell differentiation. This is the first report that maps the cytokine and master regulator pattern of the Th17 subset after its differentiation from naïve human CD4 T cells under the influence of VIP, examining their functionality and describing how VPAC receptors are modulated during Th17 differentiation.
Materials and Methods

Isolation of Naïve Human T Cells
Naïve CD4 + T cells were isolated from the human cord blood from six healthy donors. The study was performed according to the recommendations of the Declaration of Helsinki. The samples were obtained after the donors had signed a written informed consent and were approved by the ethics committee of the Transfusion Center (Comunidad de Madrid). For CD4 + T cells isolation, density gradient centrifugation by FicollHypaque (Sigma Aldrich) and negative selection using a commercial isolation system (RosetteSep® Human CD4 + T Cell Enrichment Cocktail from StemCell Technologies) were combined. Naïve T cells were then positively isolated with a MACS Cell Isolation kit using CD45RA + MicroBeads (Miltenyi Biotec). The purity exceeded 90 %.
In Vitro Th17 Cell Polarization
Cells were cultured at 4 × 10 4 cells/well in RPMI 1640 GlutaMAX media (Life Technologies) supplemented with 10 % fetal bovine serum (Lonza) and 1 % penicillin/ streptomycin (Life Technologies). Cells were expanded with anti-CD3 and anti-CD28-coated beads (Life Technologies). Three types of cultures were established: Nonpolarizing conditions; Th17-polarizing conditions in the presence of human recombinant TGF-β (2 ng/ml; eBioscience), human recombinant IL-23 (10 ng/ml; eBioscience), human recombinant IL-6 (10 ng/ml; eBioscience), human recombinant IL-1β (10 ng/ml; eBioscience), anti-IL-4 (2 μg/ml; BD Pharmingen), and anti-IL-12p35 (2 μg/ml; R&D System); and VIP/Th17-polarizing conditions as above plus 10 nM of VIP (Polypeptide Group VIP (3-7)/GRF (8-27)] was added in addition to VIP. On day 4 of culture, medium was replaced with one containing the recombinant cytokines, peptides, and antibodies corresponding to each treatment but without anti-CD3 and anti-CD28 to avoid overstimulation.
RNA Extraction and Semiquantitative Real-Time PCR
For total RNA extraction, we used the TriReagent method (Sigma Aldrich). Total RNA (2 μg) was reverse transcribed using a High Capacity cDNA Reverse Transcription Kit (Life Technologies). Semiquantitative real-time polymerase chain reaction (PCR) analysis for all molecules tested was performed using TaqMan Gene Expression Master Mix (Life Technologies), with the exception of IL-22, which was tested using SYBR® Green PCR Master Mix (Life Technologies) (Table 1) . β-Actin was used as an endogenous reference gene. For each sample, we compared the amount of target mRNA normalized to the endogenous reference, using the formula 2 −ΔΔCt .
Measurement of Cytokines
Cells were restimulated on day 7 with 20 ng/ml phorbol myristate acetate (PMA) and 0.5 μM ionomycin (Sigma Aldrich) for 6 h. After stimulation, the levels of IL-17A, IL-21, IL-22, IFN-γ, IL-9, IL-2 (eBioscience), and IL-10 (Diaclone) were analyzed by enzyme-linked immunosorbent assay (ELISA).
Measurement of BrdU Incorporation
Cell proliferation was determined by incorporation of Bromodeoxyuridine (BrdU) into DNA using the Cell Proliferation Assay Kit (Roche). On days 4 and 7 of culture, cells were incubated with 10 μM BrdU for 24 h. Absorbance at 450 nm with a 690-nm reference was measured in a plate reader (UVM 340 microplate reader, ASYS HITECH GMBH).
Measurement of Cell Viability
Viability of cells was determined by trypan blue dye exclusion assay. On day 7 of culture, cells were collected and incubated with trypan blue solution (1:1) and the number of viable and dead cells was counted. Cell viability was calculated as the relationship between the number of viable cells on day 7 and the total number of cells cultured.
Flow Cytometry Analysis
After 7 days of culture, cells were collected from the culture plates and labeled with phycoerythrin-conjugated CCR6 (clon 11A9, BD Pharmingen) at 4°C for 30 min. Cells were washed, fixed, and permeabilized with Transcription Factor Buffer Set (BD Pharmingen) for 50 min at 4°C. Then, cells were labeled with Alexa Fluor 488-conjugated T-bet (O4-46, BD Pharmingen), allophycocyanin-conjugated RAR-related orphan receptor C (RORC; clone AFKJS-9, eBioscience) and Brilliant Violet 711-conjugated Ki67 (clone Ki-67, BioLegend) at 4°C for 1 h in perm/wash buffer. Autofluorescence and isotype controls were set up to define nonspecific fluorescence. Technologies) . Cells were counterstained with 1 μg/ml Hoechst to visualize nuclear bodies.
Statistical Analysis
The t test was used to compare different cell populations, and correlations were conducted using Pearson's coefficient test. Both statistical tests were done using GraphPad Prism Version 4.0 software (GradphPad Software).
Results
In Vitro Differentiation of Th17 Cells and Its Maintenance by VIP
First, we analyzed the features of differentiated Th17 cells by checking protein expression of different cytokines in the supernatants after 7 days of culture (Fig. 1a) . Signature cytokines of the Th17 subset such as IL-17A or IL-21 were significantly increased in the supernatants of Th17-polarized cells. Surprisingly, the Th17-polarized cells secreted significantly less IL-22 compared with nonpolarized cells. IFN-γ levels in supernatants of Th17-polarized cells were lower with respect to nonpolarized cells. Analysis of IL-2 and IL-10 production showed no clear differences between Th17-polarized and nonpolarized cells. Finally, IL-9 determination showed higher protein levels in Th17-polarized cells than in the nonpolarized cells. Thus, Th17-polarized cells in this in vitro system are characterized by high expression levels of IL-17A, IL-21, and IL-9 and low levels of IFN-γ and IL-22. Cytokine levels in VIP/Th17-polarized cells were similar to Th17-polarized cells, with the exception of IL-17A protein, .001 Th17-polarized versus VIP/Th17-polarized cells which was lower in the Th17-polarized cells in the presence of VIP. Nevertheless, IL-17A levels were significantly higher in these cells than in nonpolarized cells.
We analyzed the mRNA expression of IL-21R, IL-23R, and IL-12Rβ2 (Fig. 1b) . Regarding IL-21R expression, similar levels of expression were determined in all cases. Our data also showed higher IL-23R mRNA levels in Th17-polarized cells compared with nonpolarized cells. VIP significantly increased the expression of IL-23R. IL-12 receptor expression was determined by the analysis of the IL-12Rβ2 subunit. The results showed significantly decreased IL-12Rβ2 expression in both Th17-and VIP/Th17-polarized cells.
We also examined the mRNA expression of transcription factors of different Th subsets (Fig. 2) . Results showed that RORC, RAR-related orphan receptor A (RORA), and aryl hydrocarbon receptor (AhR) expression were higher in Th17-polarized than in nonpolarized cells. Analysis of STAT3 expression did not show significant differences between the two conditions. In contrast, Foxp3 and T-box transcription factor (Tbx21/T-bet) expression was lower in Th17-polarized than nonpolarized cells. Interestingly, VIP/Th17-polarized cells showed higher RORC, RORA, and STAT3 expression than Th17-polarized cells. In summary, the presence of VIP during human Th17 differentiation could maintain their Th17 commitment and significantly enhances IL-23R, RORC, RORA and STAT3 expression.
Functional Features of In Vitro Human Th17-Polarized Cells: Modulation by VIP Recent studies have begun to shed light on the heterogeneity (pathogenic or nonpathogenic phenotype) and inherent phenotypic instability of Th17 subsets (McGeachy et al. 2007; Murphy and Stockinger 2010; Sundrud and Trivigno 2013) . Different profiles of cytokines expressed by Th17 cells are related to the pathogenic or nonpathogenic phenotype of these cells, thus we determined the correlations between several cytokines, associated with proinflammatory or antiinflammatory Th17 profiles, with IL-17 and RORC (Fig. 3) . IL-17A levels were positively correlated with IL-10, IL-9, and IL-21 levels, either in the presence or absence of VIP, with a Pearson's coefficient (r) near 1.0 in all cases. Negative correlations were seen between IL-2 and IL-17A and between RORC and IL-22 (Pearson's coefficient close to −1) in both cases. Conversely, considering the balance of Th17/Th1, only when VIP is added to the cultures, IFN-γ and Tbx21 expressions were negatively correlated to the expression of IL-17A and RORC, respectively (Fig. 4a) . Flow cytometric analysis of RORC-and T-bet-expressing cells on day 7 showed that 78.8 and 81.7 % of Th17-and VIP/Th17-polarized cells, respectively, were positive for RORC but negative for T-bet (Fig. 4b) Functional features of Th cells depend on their proliferation and homing capacity. Hence, we also tested their proliferation rate by analyzing the incorporation of BrdU into DNA on days 4 and 7 (Fig. 5a ). There were no significant differences between Th17-and VIP/Th17-polarized cells on day 4, whereas on day 7 Th17-polarized cells had higher levels of BrdU incorporation than nonpolarized cells. Interestingly, at day 7, the presence of VIP during the Th17 polarization of the naïve Th cells increased their proliferation rate compared with nonpolarized and Th17-polarized cells. In addition, we determined the cell viability of our cells on day 7. No differences were found in the cell viability between nonpolarized cells and Th17-polarized cells and between Th17-polarized and VIP/ Th17-polarized cells (Fig. 5a ). In addition, we measured the proportion of cells that expressed RORC and the proliferation marker Antigen KI-67 (Ki67) by flow cytometric analysis (Fig. 5b) . Around 83 % of total cells were double positive for RORC and Ki67. Almost all RORC cells were actively proliferating. No differences were observed when VIP was added to the cultures.
We explored the homing capacity of the Th17 cells by studying the expression of the chemokine receptor CCR6. Double positive RORC/CCR6 cells were detected on Th17-polarized (74.8 %) and in VIP/Th17-polarized cells (77.3 %) (Fig. 5c) indicating that Th17-polarized cells have a migration capacity and that VIP preserves their homing capacity. We tested the expression of VPAC 1 and VPAC 2 receptors for VIP. As Fig. 6a shows, VPAC 1 expression is downregulated during T cell culture under CD3 and CD28 stimulation whereas VPAC 2 expression is maintained with Th17 polarization. The ratio between mRNA expression of VPAC 2 and VPAC 1 receptors was significantly increased in activated/expanded cells with respect to CD4 + CD45RA + T cells after 7 days of culture. This ratio was close to 1.0 in nonpolarized cells; however, it was significantly increased in Th17-and VIP/ Th17-polarized cells. VIP/Th17-polarized cells increased the expression of both receptors but not significantly. The VPAC 1 increase in VIP/Th17-polarized cells was of greater magnitude compared with the VPAC 2 increase; consequently, the VPAC 2 /VPAC 1 ratio was significantly less than in Th17-polarized cells. VPAC receptor expression was corroborated at the protein level by immunocytochemical analysis (Fig. 6b) . We detected expression of both VPAC 1 and VPAC 2 in naïve Th cells and Th17-polarized cells. No staining was observed when isotype controls were used. These results confirmed the receptor pattern observed at the mRNA level. In summary, VPAC 1 could be the main receptor involved during the onset of Th17 generation, whereas Th17 differentiation induces a switch on VIP receptors, with VPAC 2 being the main receptor expressed after the differentiation of Th17 cells.
In order to test the specificity of VPAC receptor involvement in the effect of VIP during Th17-polarization, we used specific agonists and one antagonist (Fig. 7) . The presence of VPAC 1 antagonist during the differentiation of VIP/Th17 cells significantly reduced IL-17A, STAT3, and RORC VIPstimulated mRNA expression. RORA was also reduced but not significantly. In Th17-polarized cells, the VPAC 1 agonist significantly augmented IL-17A, RORC, RORA, and STAT3 mRNA expression compared with Th17-polarized cells. In Th17-polarized cells, the VPAC 2 agonist induced an increase in the expression of mRNA in all molecules tested with the exception of STAT3. 
Discussion
Th17 cells were initially described as the key pathogenic element in several autoimmune diseases (Korn et al. 2009; Hirota et al. 2012; Marwaha et al. 2012) . Conversely, new evidence suggests that, depending on the microenvironment, Th17 cells can alter their differentiation program, inducing either protective/anti-inflammatory or proinflammatory responses (Ghoreschi et al. 2011; Marwaha et al. 2012; Sundrud and Trivigno 2013) . How different factors of an inflammatory microenvironment can modulate differentiation, function or pathogenicity of human Th17 is still unclear and requires further attention. Given the known immunomodulatory and anti-inflammatory role of VIP in several inflammatory and autoimmune disorders, we report for the first time the influence of this neuropeptide on human Th17 cell differentiation and function. Many studies have examined Th17 differentiation in vitro, both in mouse and human. Although there are discrepancies between different authors about the importance of some cytokines, it is clear that IL-6, IL1-β, and IL-21 are involved in human Th17 differentiation (Korn et al. 2009; Ganjalikhani et al. 2011; Hirota et al. 2012) . The implication of TGF-β in this process is associated with the pathogenicity, or lack Ghoreschi et al. 2011; Zuñiga et al. 2013) . Despite its implications in their potential pathogenicity (Lee et al. 2012) , the presence of IL-23 is necessary for the stabilization of Th17 cells (Korn et al. 2009 ). In this sense, McGeachy et al. suggest that when cells are polarized in the presence of TGF-β, IL-6, and IL-23, the effect of the former are predominant with respect to IL-23 and this effect is related with a nonpathogenic phenotype (McGeachy et al. 2007) . For these reasons, we used IL-6, IL1-β, IL-21, TGF-β, and IL-23 in our in vitro human Th17 differentiation model.
As expected, a main increase in IL-17A and IL-21 cytokines and the transcription factors RORC and RORA were confirmed in Th17-polarized cells. Indeed, a positive correlation between IL-21 and IL-17A was observed. By contrast, a decrease in IL-22 levels was detected in Th17-polarized cells. A negative correlation between IL-22 and RORC was observed in Th17-polarized cells. In accordance with these findings, it has been described that T cells restimulated in the presence of TGF-β and IL-6 did not induce IL-22 expression (McGeachy et al. 2007 ). Related to IL-2 expression, results showed a slight tendency to decrease IL-2 secretion and a negative correlation between IL-2 and IL-17 in Th17-polarized cells. IL-2, a survival factor of Th cells, inhibits Th17 differentiation at early stages, but can expand Th17 cells at a late stage (Amadi-Obi et al. 2007; Korn et al. 2009 ). Their high expression levels in Th17 cells have been associated with + T cells on day 0 and Th17-polarized cells on day 7. Nuclei were counterstained with Hoechst (blue) and receptors were stained with Alexa Fluor 488-conjugated secondary antibody (green) and Alexa Fluor 594-conjugated secondary antibody (red) for VPAC 1 and VPAC 2 , respectively. One representative example of three is shown a pathogenic phenotype in these cells (Ghoreschi et al. 2011; Zuñiga et al. 2013) . Meanwhile, similar levels of IL-10 were detected in nonpolarized and Th17-polarized cells. By contrast, the IL-9 levels were increased in Th17-polarized cells. A positive correlation between IL-10 and IL-17 and between IL-9 and IL-17 levels appears in Th17-polarized cells. The production of IL-10 and IL-9 by Th17 cells points to their potential nonpathogenic/anti-inflammatory phenotype (Ghoreschi et al. 2011; Zuñiga et al. 2013) . In this sense, Th17 cells activated in the presence of TGF-β and IL-6 secrete IL-17 and IL-10, suggesting a potential regulatory function for these cells or a possible regulatory mechanism to counteract their pathogenic potential (McGeachy et al. 2007 ). In addition, it has been demonstrated that IL-9 nonsecreting Th17 cells were more pathogenic than IL-9 secreting Th17 cells (Beriou et al. 2010) . With regard to the cytokine receptor, we observed higher IL-23R mRNA levels in Th17-polarized cells than in nonpolarized cells. Therefore, Th17-polarized cells are able to respond to IL-23, the cytokine necessary for the stabilization of this subset. Different reports relate IL-23R expression to the pathogenicity of Th17 cells (Lee et al. 2012; Zuñiga et al. 2013 ). However, this receptor is not exclusive of pathogenic Th17 cells, but the overexpression of IL-23R is related to a pathogenic/proinflammatory phenotype (Ghoreschi et al. 2011; Lee et al. 2012; Zuñiga et al. 2013) . Aside from RORC and RORA, another transcription factor closely related to the Th17 subset is AhR. As has been previously described, AhR expression was significantly increased in Th17-polarized cells (Veldhoen et al. 2008) . Ghoreschi et al. showed that Th17 cells, differentiated in the presence of TGF-β, express high levels of AhR and demonstrated that these cells are less pathogenic than Th17 cells differentiated in the absence of TGF-β that do not express AhR (Ghoreschi et al. 2011) . Taking into account all of these data, our data show that Th17 cells differentiated in our culture conditions present the following characteristics of a nonpathogenic/anti-inflammatory profile: an increase in IL-9 secretion, AhR expression, and a decrease in IL-22 and IFN-γ secretion and T-bet expression. In addition, we demonstrated positive correlations between IL-17 and cytokines related to nonpathogenic phenotype (IL-17 and IL-10, IL-17, and IL-9) and a negative correlation with pathogenic indicators (IL-17 and IL-2 and RORC and IL-22).
From the standpoint of plasticity and heterogeneity, Th17 cells are closely related to the Th1 subset (Murphy and Stockinger 2010; O'Shea and Paul 2010) . The levels of IFN-γ and Tbx21 were decreased in Th17-polarized cells. It has been suggested that TGF-β downregulates Tbx21 expression and as a consequence IFN-γ expression (Ghoreschi et al. 2011; Zuñiga et al. 2013) , decreasing IFN-γ + /IL-17 + doublesecreting Th17 cells (Ganjalikhani et al. 2011) . A low percentage of RORC + /T-bet + double-positive cells was observed in our cultures. Moreover, IL-12Rβ2 expression was significantly decreased after Th17-differentiation, in agreement with (Korn et al. 2009 ). On the basis of all of these findings, we document a decrease in Th1 profile of Th17 cells polarized in these in vitro conditions. This fact is related with a nonpathogenic/anti-inflammatory phenotype, since conversion of Th17 to a Th1 phenotype can promote the pathogenic potential of these cells.
Proliferation analysis showed a greater proliferation in Th17-polarized cells than in nonpolarized cells on day 7. In addition, we confirmed that around 83 % of total cells were double positive for RORC and Ki67. Therefore, in our culture conditions, almost all RORC cells were actively proliferating. Although it has been described that Th17 cells have a low ability to proliferate and to produce IL-2 in response to combined CD3 and CD28 stimulation (Santarlasci et al. 2012 ), Th17 cells polarized in our cultures show high proliferation rate and secreted IL-2. This fact could be explained in part by the increase in the expression of IL-23R during differentiation process and their capacity to answer to IL-23, cytokine associated with the expansion of Th17 subset (Zhu and Paul 2008) . In addition, differences in culture conditions such as the stimulation conditions, the cytokines used in the polarization, the time of the culture, or the method used to check the proliferation, could explain this discrepancy.
In addition to previous analyses, we checked the homing capacity of the Th17 cells through the analysis of the expression of the chemokine receptor CCR6, which is the most important homing receptor for Th17 cells. This chemokine receptor allows their migration to an inflammatory microenvironment in response to CCL20 (Acosta-Rodriguez et al. 2007; Korn et al. 2009 ). Double-positive RORC/CCR6 cells were detected in Th17-polarized cells. These results indicate that Th17 cells polarized in our in vitro culture conditions have the capacity of respond to CCL20.
VIP plays several modulatory roles in many physiological processes in the immune system. It shows predominantly antiinflammatory and immunomodulatory actions, modulating the innate and the adaptive responses. Related to Th subsets, it has been described that VIP is able to modulate Th1, Th2, or iTreg cells (Gomariz et al. 2006; Gutiérrez-Cañas et al. 2008; Jimeno et al. 2010 Jimeno et al. , 2011 . In vitro and ex vivo studies with mice demonstrated that VIP can promote the Th17 subset, over the Th1 subset (Yadav et al. 2008; Jimeno et al. 2011) . Our results show that in human VIP/Th17-polarized cells, the IL-17A secretion was decreased. This decrease in IL-17A protein expression in the presence of VIP has been described previously (Jimeno et al. 2011) . However, results show that VIP induces the expression of IL-17A mRNA levels. Posttranscriptional regulation mechanisms could be involved in this discrepancy, but future studies are needed to clarify this. Related to cytokine receptor expression, IL-23R mRNA expression was increased in the presence of VIP. As mentioned above, the expression of IL-23R indicates that cells are able to respond to IL-23, the cytokine necessary for the stabilization of this subset. Although several reports have associated the overexpression of IL-23R with pathogenicity of Th17 cells (Ghoreschi et al. 2011; Lee et al. 2012; Zuñiga et al. 2013) , the expression of IL-23R is not exclusive of pathogenic Th17 cells. In this sense, the increase in IL-23R expression shown in the presence of VIP could indicate a greater stabilization of Th17-polarized cells generated in these culture conditions. On the other hand, our results show that RORC, RORA, and STAT3 were significantly increased in the presence of VIP. As the lineage-defining transcription factors of the Th17 cells are RORC and RORA (Yang et al. 2008) , the increase in expression of both in the presence of VIP show that this neuropeptide promotes Th17 differentiation in our culture conditions. In addition, it has been described that STAT3 is related to IL-23R, RORC, and RORA expression (Harmar et al. 2012) . For this reason, an increase in STAT3 expression in cells treated with VIP could indicate that VIP supports Th17 cells. Conversely, in the presence of VIP, no differences in the expression of IL-22 were detected in the Th17-polarized cells, but were significantly less expressed than in nonpolarized cells. In this sense, it has been reported that VIP decreases IL-22 production by Th17 cells (Ding et al. 2012 ) but, conversely, increases IL-22 expression during mouse Th17 differentiation (Yadav et al. 2008) . Regarding the heterogeneity of Th17 cells, it has been described that VIP promotes Th17 over the Th1 subset in mouse (Jimeno et al. 2011 ) and in a model of autoimmune diabetes (Jimeno et al. 2010) . A positive correlation between IFN-γ and IL-17A and between Tbx21 and RORC was observed in Th17-polarized cells. This may indicate a slight tendency toward a Th1 shift in the present culture conditions. Recent studies highlight the importance of the plasticity of Th17 cells in the Th1 phenotype (Lee et al. 2008; Lexberg et al. 2010; Hirota et al. 2012; Sundrud and Trivigno 2013) . Conversion of Th17 to the Th1 phenotype might contribute to the pathogenic potential of these cells. Analysis of the Th17/Th1 profile in the presence of VIP showed that these correlations were negative in VIP/ Th17-polarized cells, which also show a decrease in RORC + / T-bet + double-positive cells, indicating that in the presence of VIP, Th17 cells are less prone to differentiate to a Th1 pathogenic phenotype (Fig. 8) .
It has been shown that VIP inhibits proliferation of human CD4 + T cells and mouse erythrocyte-depleted spleen cells (Delgado et al. 1996; Jimeno et al. 2011) . However, in human, VIP can act as an inductor or inhibitor of proliferation in different human cells (Harmar et al. 2012) . Our results using BrdU indicate that VIP promotes the proliferation rate of Th17-polarized cells at day 7. Moreover, we determined the cell viability on day 7 and found no differences between Th17-polarized cells and VIP/Th17-polarized cells. Thus, we confirmed that the VIP effect was due to a proliferation increase and not a cell viability increase. Conversely, the analysis of Ki67/RORC double-expressing cells showed that this expression in the presence of VIP is not altered. This is not unexpected since BrdU is incorporated into DNA only during the S phase of the mitotic process whereas Ki67 is expressed for its whole duration. Therefore, a possible effect of VIP only during the S phase could be lost in Ki67 expression analyses given the high expression levels of this protein in Th17-polarized cells. In summary, the presence the VIP caused an increase in the proliferation rate of Th17-polarized cells (Fig. 8) . This result is according to above mentioned results and they indicate that VIP promotes the Th17 population in our culture conditions. These findings are consistent with previous in vitro and ex vivo studies in mice that demonstrated that VIP can promote the Th17 subset (Yadav et al. 2008; Jimeno et al. 2011) . In addition, studies with different mice models of autoimmune diseases have shown that VIP is able to promote the Th17 differentiation in vivo (Abad et al. 2005; Leceta et al. 2007 ). Taking account that there are endogenous sources of VIP, as nerves fibers and immune cells, this neuropeptides could modify human Th17 profile in vivo.
In relation to VIP receptor expressions, CD4 + T cells have been studied previously (Vomhof-Dekrey and Dorsam 2008; Dorsam et al. 2011 ). Our results demonstrate the interesting finding that the VPAC receptor pattern changed in our cultures. Unlike naïve Th cells, Th17-polarized cells predominantly express the VPAC 2 receptor. It has been described that naïve human and mouse CD4 + T cells predominantly express the VPAC 1 receptor and after clonal expansion there is a downregulation of this receptor (Vomhof-Dekrey and Dorsam 2008; Dorsam et al. 2011) . Changes in the pattern of VIP receptors with the degree of activation/maturation of the cells have been described Vomhof-Dekrey and Dorsam 2008; Dorsam et al. 2011) . Although an increase in the VPAC 2 /VPAC 1 ratio was observed in nonconditioned cells, this increase was significantly higher in Th17-polarized cells. In addition, Yadav et al. noted that VIP-induced Th17 differentiation was mainly mediated through the VPAC 1 receptor (Yadav et al. 2008 ). In addition, in our cultures, the high levels of VPAC 1 expression in naïve cells may be involved in the differentiation process. Differential expression of VIP receptors in human Th cells is poorly understood and future studies are needed to clarify whether Th17-polarized cells express more VPAC 2 or VPAC 1 . Conversely, we tested the specificity of VIP receptors involvement in the effect of VIP during Th17-polarization using specific agonists and antagonist (Fig. 8) . The specific agonists for VPAC 1 and VPAC 2 were previously and extensively used with a high affinity for each receptor subtype (Couvineau and Laburthe 2012; Harmar et al. 2012 VIP (3-7)/GRF (8-27)], has 200-to 1,000-fold greater affinity for the human VPAC 1 than for the human VPAC 2 receptor. However, it does not stimulate the adenylate cyclase activity of any membrane preparation in a concentration range from 0.1 to 10.000 nM (Gourlet et al. 1997; Ceraudo et al. 2012) . As a consequence, this antagonist does not induce a biological effect per se (Baun et al. 2011) . By examining the functionality of VPAC receptors, we can conclude that the expressions of important molecules of Th17 cells such as RORA, RORC, or IL-17A are upregulated by VIP through VPAC 1 and VPAC 2 receptors. Meanwhile, VIP exerts upregulation of IL-23R, a crucial molecule for Th17 stabilization in the late stages of Th17 differentiation, through the VPAC 2 receptor. However, the VPAC 1 receptor was shown to mediate STAT3 upregulation, according to a previous study that describes the effect of VIP on STAT3 in human renal cell carcinoma (Vacas et al. 2012 ).
In conclusion, our results demonstrate that VIP may maintain the nonpathogenic/anti-inflammatory profile of human Th17 cells; increase their proliferation rate; and reduce the Th1 potential of these cells. In addition, Th17 differentiation induces a switch in VPAC receptor expression pattern. These results highlight a novel translational view in inflammation/ autoimmune diseases, which adds new reasons to consider VIP as a therapeutic agent with great potential in the clinical setting.
